• Wuhan HHD NSI-189 Phosphate Freebase /NSI 189 Phosphate Base
  • Wuhan HHD NSI-189 Phosphate Freebase /NSI 189 Phosphate Base
Wuhan HHD NSI-189 Phosphate Freebase /NSI 189 Phosphate Base
  • Wuhan Hengheda Pharm Co.,Ltd
  • China
  • Immediately after payment
  • 10kg/month

NSI-189 is neurogenic and nootropic research agent that was developed from nicotinamide and pyrazine. Randomized controlled trials have shown that it stimulates neurogenesis or neuronal cell production in the brain. In animal studies, it has also been shown to increase the volume of hippocampus by 20% thereby reversing behavioral symptoms of depression. Such studies have shown that it may be an effective treatment for depression. It is also thought to be a promising treatment for other condition including post-traumatic stress disorder (PTSD), Alzheimer’s disease and age-related cognitive problems.
NSI-189 is an experimental antidepressant. Neuralstem, Inc. is currently testing it for use in major depression, in addition to treating cognitive impairments, and brain degeneration. It may induce specific brain regeneration.
NSI-189 is most likely selective only to two nervous system controlling regions in the brain (hippocampus, subventricular zone)

NSI-189 Phosphate Freebase /NSI 189 Phosphate Base

Potential Treatment for Cognitive Impairment and Angelman Syndrome

Treatment of normal mouse brain slices with NSI-189 produced a concentration and time dependent enhancement of the magnitude of long term potentiation (LTP), a measure of synaptic plasticity, which is an in vitro biomarker of memory. Additionally, NSI-189-induced LTP enhancement requires protein synthesis, suggesting structural synaptic plasticity.

NSI-189 treatment of brain slices from mice with a genetic defect that models Angelman Syndrome (which in humans leads to inherited intellectual disability) restored LTP to normal levels.

NSI-189 treatment ameliorated behavioral and memory function and preserved hippocampal neurogenesis in a rat model of cognitive impairment induced by irradiation.

Potential Treatment for Type 1 and Type 2 Diabetes

NSI-189 was demonstrated to be effective in the prevention and reversal of peripheral neuropathies in a mouse model of Type 1 and preventative in a mouse model of Type 2 diabetes. Data from these studies, which includes reversal of neuropathic pain and decreased nerve conductance associated with the onset of diabetic symptoms, suggest that NSI-189 may have broad applicability in the treatment of central and peripheral neuropathies arising from diverse etiologies.

Potential Treatment for Ischemic Stroke

Oral administration of NSI-189 to mice with ischemic stroke led to a significant increase in neurogenesis in the hippocampus accompanied by a significant recovery from motor deficit. This evidence suggests that NSI-189 can induce recovery from stroke-induced brain damage. The improvements were maintained post the termination of NSI-189 therapy for an additional 12-week, drug-free, observational period. The sustained improvement suggests that NSI-189 initiated a host brain repair mechanism enabling tissue remodeling of the stroke brain. NSI-189 demonstrated the upregulation of growth factors such as stem cell factor (SCF) and brain-derived neurotrophic factor (BDNF), as well as increasing neurite outgrowth.

Do we have the test reports for our products provided by the independent third party?
Every batch of our product was tested by authorized independent third party, Analysis testing center, Shanghai branch, Chinese Academy of Science. We send goods to customers with test report and COA. Our products were also tested by American Analytical Chemistry Laboratories and Chromadex too....more
Get the latest price? We'll respond as soon as possible(within 12 hours)

Privacy policy

close left right